Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozenoxacin - Ferrer/Maruho

Next Previous
X
Search
Drug Profile

Ozenoxacin - Ferrer/Maruho

Alternative Names: Dubine; GF-001001-00; M 5120; M 512101; M-512102; Ozadub; OZANEX; T-3912; Xepi; Zebiax

Latest Information Update: 11 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toyama Chemical
  • Developer Cipher Pharmaceuticals; Ferrer; Maruho
  • Class Antiacnes; Antibacterials; Cyclopropanes; Pyridines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris; Impetigo
  • Registered Skin and soft tissue infections

Most Recent Events

  • 11 Dec 2024 No development reported - Phase-III for Impetigo in Japan (Topical)
  • 16 Apr 2021 No development reported - Phase-II for Skin and soft tissue infections in France, Czech Republic, Germany, Spain, Italy (Topical)
  • 16 Apr 2021 No development reported - Phase-III for Impetigo in South Africa, Romania, Puerto Rico, India, Ukraine, Russia (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top